Share This Author
Biology and therapeutic advances for pediatric osteosarcoma.
The authors review the state of the art management for patients with osteosarcoma in North America and Europe including the use of limb-salvage procedures and reconstruction as well as discuss the etiologic and biologic factors associated with tumor development.
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
A significant association between high ezrin expression and poor outcome in pediatric osteosarcoma patients is found and Ezrin-mediated early metastatic survival was partially dependent on activation of MAPK, but not AKT.
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
- M. Isakoff, S. Bielack, P. Meltzer, R. Gorlick
- Medicine, BiologyJournal of Clinical Oncology
- 24 August 2015
Biologic, preclinical, and clinical trial efforts will be described along with future international collaborative strategies to improve outcomes for patients who develop this challenging tumor.
Osteosarcoma: a review of diagnosis, management, and treatment strategies.
Modern multi-agent chemotherapy has resulted in the greatest improvement in overall survival to date, and it is very likely that future improvements in survival will arise from combination-targeted chemotherapy in addition to conventional treatment.
Detectable clonal mosaicism and its relationship to aging and cancer
Large chromosomal abnormalities in a subset of clones in DNA obtained from blood or buccal samples underscore the time-dependent nature of somatic events in the etiology of cancer and potentially other late-onset diseases.
Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
- R. Gorlick, A. Huvos, P. Meyers
- Medicine, BiologyJournal of clinical oncology : official journal…
- 1 September 1999
The correlation of HER2/erbB-2 expression with histologic response to preoperative chemotherapy and event-free survival in this study suggests that HER2-erb B-2 should be evaluated prospectively as a prognostic indicator and clinical trials of antibodies that target this receptor should be considered for the treatment of osteosarcoma.
Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma.
The absence of a detectable TMM may identify a favorable clinical subset of OS patients and the likelihood of detecting correlations between TMMs and clinical outcome in studies of certain other tumor types might be improved if, in addition to TA, ALT is included in future analyses.
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse.
Alterations in p53 or p16/p14ARF are found in a fourth of ES cases and define a subset with highly aggressive behavior and poor chemoresponse, which is the first combined prognostic analysis of these three molecular parameters in ES.
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
The expression of Programmed Death Ligand 1 (PD-L1) was examined and the tumor immune microenvironment was defined to assess the prognostic utility in osteosarcoma and expression was correlated with immune cell infiltration and event-free-survival (EFS).
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
- R. Gorlick, P. Anderson, B. Anderson
- MedicineClinical cancer research : an official journal of…
- 15 November 2003
A meeting was held in Bethesda, Maryland on November 29-30, 2001 to review the current state of knowledge regarding OS biology and discuss the available tissue resources and the appropriate methods for analysis of OS samples for the conduct of biology studies.